Your web browser is out of date.

For your security and improved experience online, please update your browser.
Update your browser

Diabetes on the Net is intended for healthcare professionals

back to main site

Improving cardiovascular outcomes in type 2 diabetes with SGLT2 inhibitors – What is the role of the cardiologist?

Please sign in below:

The next event will begin in:

Days
Hours
Minutes
Seconds

The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional webcast, including speaker honoraria and presentation development support where applicable. Boehringer Ingelheim andLilly Diabetes Alliance products will be discussed in this webcast.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 3281627 (freephone)

Adverse events should be reported. Reporting forms and information can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue 
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 01 2913960 Fax: +44 1344 742661
or by email: PV_local_UK_Ireland@boehringer-ingelheim.com
*

Defined as new patients prescribed JARDIANCE, patients switched to JARDIANCE from another type 2 diabetes treatment or JARDIANCE added to another type 2 diabetes treatment

Reference
1. Data on File. IQVIA new patient opportunity data April 2019. Boehringer Ingelheim.
2. Jardiance Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/28973 (accessed June 2020)

For prescribing information UK – IE

Job code: PC-GB-101934

Date of prep: June 2020

The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional webcast, including speaker honoraria and presentation development support where applicable. Boehringer Ingelheim and Lilly Diabetes Alliance products will be discussed in this webcast.

Marketing and organisational support has been provided by Omniamed Communications.

© Copyright OmniaMed Communications Ltd. All rights reserved

Privacy policy / Terms and conditions

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

Confirm
* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.